TY - JOUR
T1 - Open source drug discovery- A new paradigm of collaborative research in tuberculosis drug development
AU - Bhardwaj, Anshu
AU - Scaria, Vinod
AU - Raghava, Gajendra Pal Singh
AU - Lynn, Andrew Michael
AU - Chandra, Nagasuma
AU - Banerjee, Sulagna
AU - Raghunandanan, Muthukurussi V.
AU - Pandey, Vikas
AU - Taneja, Bhupesh
AU - Yadav, Jyoti
AU - Dash, Debasis
AU - Bhattacharya, Jaijit
AU - Misra, Amit
AU - Kumar, Anil
AU - Ramachandran, Srinivasan
AU - Thomas, Zakir
AU - Brahmachari, Samir K.
N1 - Funding Information:
The authors thank all the OSDD members for their active participation in OSDD and Council of Scientific and Industrial Research , India for funding (Grant No. HCP0001 ).
PY - 2011/9
Y1 - 2011/9
N2 - It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.
AB - It is being realized that the traditional closed-door and market driven approaches for drug discovery may not be the best suited model for the diseases of the developing world such as tuberculosis and malaria, because most patients suffering from these diseases have poor paying capacity. To ensure that new drugs are created for patients suffering from these diseases, it is necessary to formulate an alternate paradigm of drug discovery process. The current model constrained by limitations for collaboration and for sharing of resources with confidentiality hampers the opportunities for bringing expertise from diverse fields. These limitations hinder the possibilities of lowering the cost of drug discovery. The Open Source Drug Discovery project initiated by Council of Scientific and Industrial Research, India has adopted an open source model to power wide participation across geographical borders. Open Source Drug Discovery emphasizes integrative science through collaboration, open-sharing, taking up multi-faceted approaches and accruing benefits from advances on different fronts of new drug discovery. Because the open source model is based on community participation, it has the potential to self-sustain continuous development by generating a storehouse of alternatives towards continued pursuit for new drug discovery. Since the inventions are community generated, the new chemical entities developed by Open Source Drug Discovery will be taken up for clinical trial in a non-exclusive manner by participation of multiple companies with majority funding from Open Source Drug Discovery. This will ensure availability of drugs through a lower cost community driven drug discovery process for diseases afflicting people with poor paying capacity. Hopefully what LINUX the World Wide Web have done for the information technology, Open Source Drug Discovery will do for drug discovery.
KW - Drug Discovery
KW - Generics
KW - Malaria
KW - Neglected diseases
KW - Open source
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=80052698379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052698379&partnerID=8YFLogxK
U2 - 10.1016/j.tube.2011.06.004
DO - 10.1016/j.tube.2011.06.004
M3 - Review article
C2 - 21782516
AN - SCOPUS:80052698379
SN - 1472-9792
VL - 91
SP - 479
EP - 486
JO - Bulletin of the International Union Against Tuberculosis and Lung Disease
JF - Bulletin of the International Union Against Tuberculosis and Lung Disease
IS - 5
ER -